GSK (NYSE: GSK) executives acquire small share awards under plan
Filing Impact
Filing Sentiment
Form Type
6-K
GSK plc reported a series of small share acquisitions by senior executives under the company’s Share Reward Plan. On 9 December 2025, Chief Executive Officer Emma Walmsley, Chief Financial Officer Julie Brown and several other senior leaders, including the group general counsel, heads of global communications, corporate development, global supply chain, global affairs, ViiV Healthcare and the company secretary, each acquired GSK ordinary shares of 31¼ pence. The purchases combined partnership and matching shares, with individual totals ranging from 12 to 14 ordinary shares at a price of £18.0780 per share. All transactions took place on the London Stock Exchange (XLON) and are routine disclosures of dealings by persons discharging managerial responsibilities.
Positive
- None.
Negative
- None.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of December 2025
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
GSK plc (the
'Company')
Transaction notification
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Emma Walmsley
|
|
|
b)
|
Position/status
|
Chief
Executive Officer
|
|
|
c)
|
Initial
notification/ amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GSK plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£18.0780
|
7 (partnership shares)
|
||
|
£18.0780
|
7 (matching shares)
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
14 Ordinary Shares
£18.0780
|
|
|
e)
|
Date
of the transaction
|
2025-12-09
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Julie Brown
|
|
|
b)
|
Position/status
|
Chief
Financial Officer
|
|
|
c)
|
Initial
notification/ amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GSK plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£18.0780
|
6 (partnership shares)
|
||
|
£18.0780
|
6 (matching shares)
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
12 Ordinary Shares
£18.0780
|
|
|
e)
|
Date
of the transaction
|
2025-12-09
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
James Ford
|
|
|
b)
|
Position/status
|
SVP and
Group General Counsel, Legal and Compliance
|
|
|
c)
|
Initial
notification/ amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GSK plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£18.0780
|
6 (partnership shares)
|
||
|
£18.0780
|
6 (matching shares)
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
12 Ordinary Shares
£18.0780
|
|
|
e)
|
Date
of the transaction
|
2025-12-09
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Sally Jackson
|
|
|
b)
|
Position/status
|
SVP,
Global Communications and CEO Office
|
|
|
c)
|
Initial
notification/ amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GSK plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£18.0780
|
7 (partnership shares)
|
||
|
£18.0780
|
7 (matching shares)
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
14 Ordinary Shares
£18.0780
|
|
|
e)
|
Date
of the transaction
|
2025-12-09
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
David Redfern
|
|
|
b)
|
Position/status
|
President,
Corporate Development
|
|
|
c)
|
Initial
notification/ amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GSK plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£18.0780
|
7 (partnership shares)
|
||
|
£18.0780
|
7 (matching shares)
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
14 Ordinary Shares
£18.0780
|
|
|
e)
|
Date
of the transaction
|
2025-12-09
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Regis Simard
|
|
|
b)
|
Position/status
|
President,
Global Supply Chain
|
|
|
c)
|
Initial
notification/ amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GSK plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£18.0780
|
7 (partnership shares)
|
||
|
£18.0780
|
7 (matching shares)
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
14 Ordinary Shares
£18.0780
|
|
|
e)
|
Date
of the transaction
|
2025-12-09
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Philip Thomson
|
|
|
b)
|
Position/status
|
President,
Global Affairs
|
|
|
c)
|
Initial
notification/ amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GSK plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£18.0780
|
7 (partnership shares)
|
||
|
£18.0780
|
7 (matching shares)
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
14 Ordinary Shares
£18.0780
|
|
|
e)
|
Date
of the transaction
|
2025-12-09
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Deborah Waterhouse
|
|
|
b)
|
Position/status
|
CEO,
ViiV Healthcare and President, Global Health, GSK
|
|
|
c)
|
Initial
notification/ amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GSK plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£18.0780
|
7 (partnership shares)
|
||
|
£18.0780
|
7 (matching shares)
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
14 Ordinary Shares
£18.0780
|
|
|
e)
|
Date
of the transaction
|
2025-12-09
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Victoria Whyte
|
|
|
b)
|
Position/status
|
SVP
& Company Secretary
|
|
|
c)
|
Initial
notification/ amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GSK plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£18.0780
|
7 (partnership shares)
|
||
|
£18.0780
|
7 (matching shares)
|
||
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
14 Ordinary Shares
£18.0780
|
|
|
e)
|
Date
of the transaction
|
2025-12-09
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at www.gsk.com.
Registered in England & Wales:
No. 3888792
Registered Office:
79 New Oxford Street
London
WC1A 1DG
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: December
11, 2025
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|
FAQ
What did GSK (GSK) disclose in this Form 6-K filing?
GSK disclosed that several senior executives acquired small numbers of ordinary shares under the company’s Share Reward Plan and reported the details as required for persons discharging managerial responsibilities.
Which GSK executives bought shares and in what size?
Executives including CEO Emma Walmsley, CFO Julie Brown, and senior leaders such as James Ford, Sally Jackson, David Redfern, Regis Simard, Philip Thomson, Deborah Waterhouse and Victoria Whyte each acquired between 12 and 14 ordinary shares through partnership and matching awards.
At what price were the GSK shares acquired in the Share Reward Plan?
The disclosed acquisitions were made at a price of £18.0780 per ordinary share for both partnership and matching shares under the Share Reward Plan.
When and where did these GSK executive share transactions occur?
The transactions took place on 9 December 2025 and were executed on the London Stock Exchange (XLON), involving GSK ordinary shares of 31¼ pence each.
What is the nature of GSK’s Share Reward Plan mentioned in the filing?
The Share Reward Plan is an arrangement under which GSK executives acquire partnership shares and receive matching shares, leading to periodic small acquisitions of GSK ordinary shares that must be reported as transactions by senior management.
Does this GSK filing indicate a major change in ownership or capital structure?
No. The filing reports small routine acquisitions of GSK ordinary shares by several executives, with individual totals of 12 to 14 shares, and does not describe any broader change to GSK’s capital structure.